Jazz Pharma's decision to revoke U.S. patent for rival narcolepsy drug

Published Date: 02 Mar 2023

A U.S. court on Friday ordered Jazz Pharmaceuticals to revoke its patents related to its flagship narcolepsy drug Xyrem from the FDA-approved brand name drug after winning a case against Avadel foe CNS Pharmaceuticals.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Woman Loses 6-Year Battle With Mouth Tumor

2.

Lesser-known lobular breast cancer on the rise in U.S. women

3.

PSA Often Unchanged With Enzalutamide Progression

4.

Olaparib-Abiraterone in mCRPCs Selected by Biomarkers Outperforms Each Agent by Itself.

5.

To refute accusations that it failed to issue a cancer warning, Roundup's maker is asking lawmakers for assistance.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot